Rocket Pharmaceuticals, Inc.

RCKT

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
August 11, 2025

Days Left:
57

calendar

Rocket Pharmaceuticals, Inc. Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Allegations

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501’s safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial’s protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket’s securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made “several months” earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket’s common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket’s stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Rocket purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Rocket during the relevant time frame, you have until August 11, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Active Cases

Ticker Symbol Company Name Join Deadline Join
NSSC Napco Security Technologies, Inc. June 24, 2025 Join
CODI Compass Group Diversified Holdings, LLC July 08, 2025 Join
IOVA Iovance Biotherapeutics, Inc. July 14, 2025 Join
OGN Organon & Co. July 22, 2025 Join
VSTS Vestis Corporation August 08, 2025 Join
RCKT Rocket Pharmaceuticals, Inc. August 11, 2025 Join